Abstract
With the exponential increase in publications on DNA markers explaining and/or predicting response to drug therapy, the potential of pharmacogenetic testing of individual patients to optimize drug treatment is expanding. For the identification of pharmacogenetic markers, several techniques can be used. The specific method usually depends on the requirements of the study, ranging from determining one or two single nucleotide polymorphisms (SNPs) in one to ten patients, one or two SNPs in thousands of patients, several thousands of SNPs in an individual patient, or thousands of SNPs in thousands of patients. In this review we identify and evaluate the information present in the literature on genotyping assays that are currently used for pharmacogenetic analyses, and discuss the advantages and disadvantages of these techniques.
Current Pharmaceutical Design
Title: Genetic Techniques for Pharmacogenetic Analyses
Volume: 16 Issue: 2
Author(s): Tahar van der Straaten and Ron H.N. van Schaik
Affiliation:
Abstract: With the exponential increase in publications on DNA markers explaining and/or predicting response to drug therapy, the potential of pharmacogenetic testing of individual patients to optimize drug treatment is expanding. For the identification of pharmacogenetic markers, several techniques can be used. The specific method usually depends on the requirements of the study, ranging from determining one or two single nucleotide polymorphisms (SNPs) in one to ten patients, one or two SNPs in thousands of patients, several thousands of SNPs in an individual patient, or thousands of SNPs in thousands of patients. In this review we identify and evaluate the information present in the literature on genotyping assays that are currently used for pharmacogenetic analyses, and discuss the advantages and disadvantages of these techniques.
Export Options
About this article
Cite this article as:
Straaten van der Tahar and van Schaik H.N. Ron, Genetic Techniques for Pharmacogenetic Analyses, Current Pharmaceutical Design 2010; 16 (2) . https://dx.doi.org/10.2174/138161210790112755
DOI https://dx.doi.org/10.2174/138161210790112755 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Anticancer Antioxidant Regulatory Functions of Phytochemicals
Current Medicinal Chemistry Inhibitors for Proteins Endowed with Catalytic and Non-Catalytic Activity which Recognize pTyr
Current Medicinal Chemistry Dinuclear Berenil-Platinum (II) Complexes as Modulators of Apoptosis in Human MCF-7 and MDA-MB231 Breast Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Endocrine and Antineoplastic Actions of Growth Hormone-Releasing Hormone Antagonists
Current Medicinal Chemistry How to Inhibit Telomerase Activity for Cancer Therapy
Current Medicinal Chemistry - Anti-Cancer Agents HLA Class I Expression, Tumor Escape and Cancer Progression
Current Cancer Therapy Reviews FLIM-FRET for Cancer Applications
Current Molecular Imaging (Discontinued) Gold Nanoparticles in Cancer Therapy: Efficacy, Biodistribution, and Toxicity
Current Pharmaceutical Design Dynamic Contrast Enhanced Magnetic Resonance Imaging in Oncology:Theory, Data Acquisition,Analysis, and Examples
Current Medical Imaging The Emerging Role of Histology in the Choice of First-Line Treatment of Advanced Non-Small Cell Lung Cancer: Implication in the Clinical Decision-Making
Current Medicinal Chemistry Important Aspects of Post-Prandial Antidiabetic Drug, Acarbose
Current Topics in Medicinal Chemistry Dendritic Cells in Esophageal Adenocarcinoma: The Currently Available Information and Possibilities to use Dendritic Cells for Immunotherapeutic Approaches
Current Pharmaceutical Design Insights Into the Molecular Aspects of Neuroprotective Bacoside A and Bacopaside I
Current Neuropharmacology Chemosensitization of Prostate Cancer by Modulating Bcl-2 Family Proteins
Current Drug Targets Cytotoxicity and Anti-proliferative Properties of Heterocyclic Compounds Derived from Progesterone
Anti-Cancer Agents in Medicinal Chemistry 1,3,4-oxadiazole-2-thione Derivatives; Novel Approach for Anticancer and Tubulin Polymerization Inhibitory Activities
Anti-Cancer Agents in Medicinal Chemistry Use of the Semiconductor Nanotechnologies “Quantum Dots” for in vivo Cancer Imaging
Recent Patents on Anti-Cancer Drug Discovery Fibrinolysis: The Key to New Pathogenetic Mechanisms
Current Medicinal Chemistry High Frequency of the Opioid Receptor µ-1 (OPRM1) A118G Polymorphism, an Opioid Drug Therapy Related Gene, in the Indonesian Population
Current Pharmacogenomics and Personalized Medicine Biotechnological Engineering of Heparin/Heparan Sulphate: A Novel Area of Multi-Target Drug Discovery
Current Pharmaceutical Design